Urinary excretion of indican in progressive myoclonus epilepsy without Lafora bodies. The effect of sodium valproate.
Increased urinary excretion of indican was detected in earlier studies of patients with the form of progressive myoclonus epilepsy (PME) where no Lafora bodies are present in the brain and other tissues. Since then, all PME patients have been given sodium valproate and/or clonazepam. In a series of 10 patients now examined the mean excretion was on the same level as that of other epileptic and non-epileptic neurological patients (53 +/- 27 mg/g creatinine). Alternate reduction of the two drugs in one patient over a period of 24 days increased the excretion up to the high level measured earlier (96 mg/g creatinine) and caused marked worsening of the clinical condition while no remarkable changes were observed in another PME patient who received her normal medication. The highest values ever measured were found in one PME patient just before his death. In two patients who had no medication the excretion was also high but returned to the normal level during medication with sodium valproate. It is unknown at the moment whether this change is due to the improved clinical condition of the patients or to the compound itself.
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D002998:Clonazepam / Q000627:therapeutic use; D004831:Epilepsies, Myoclonic / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D007200:Indican / Q000652:urine*; D010634:Phenobarbital / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use*
D000927:Anticonvulsants; D002998:Clonazepam; D014635:Valproic Acid; D007200:Indican; D010634:Phenobarbital